$50M cell and viral vector manufacturing operation backed by Harvard

CDMOs are building gene therapy and viral vector manufacturing facilities left and right, but Harvard says it just isn’t enough, at least to serve the Boston biotech hub. That is why a host of public and private players is working on a $50 million clinical supply manufacturing facility.